LGR5 and neoplasm: Preclinical studies, including antibody-based and CAR-T approaches, have shown promising antitumor activity against LGR5-positive cells, though challenges such as tumor heterogeneity and potential toxicity to normal stem cells remain (Mueller et al., 2025).